Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Statin Comparative Studies Needed, Oregon Drug Effectiveness Review Project Suggests

This article was originally published in The Pink Sheet Daily

Executive Summary

DERP wants comparative-effectiveness study on LDL-c lowering capabilities and adverse events.

You may also be interested in...

Medco Savings Tool Spotlights Consumer Reports’ “Best Buy” Drugs

PBM will feature link to Consumer Reports Best Buy Drugs for certain medication classes.

AstraZeneca’s Crestor Targets High Risk Patients, Delivers High Sales

Crestor sales grew 47% in the second quarter; entry of generic simvastatin caused some expected “disruption” in the marketplace.

Lipitor Is Pound-Wise Versus Generic Zocor, Pfizer IDEAL Cost Study Says

When total healthcare costs are considered, atorvastatin is more cost-effective than simvastatin even when Zocor is discounted 50% from its current price, Pfizer analysis says.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts